Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives (Q35764308)

10 August 2017

Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives (English)

1 reference

10 August 2017

2

Christos Iavazzo

1 reference

10 August 2017

1

Nikolaos Vrachnis

1 reference

10 August 2017

3

Zoe Iliodromiti

1 reference

10 August 2017

4

Stavros Sifakis

1 reference

10 August 2017

Andreas Alexandrou

5

1 reference

10 August 2017

Charalambos Siristatidis

6

1 reference

10 August 2017

Charalambos Grigoriadis

7

1 reference

10 August 2017

Dimitrios Botsis

8

1 reference

10 August 2017

George Creatsas

9

1 reference

10 August 2017

4 September 2015

1 reference

Archives of Gynecology and Obstetrics

10 August 2017

1 reference

10 August 2017

293

1 reference

10 August 2017

239-246

1 reference

10 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s00404-015-3858-z

10 August 2017

0 references

cites work

Metformin and other biguanides in oncology: advancing the research agenda

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

The pathobiology of diabetic complications: a unifying mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Activation of endoplasmic reticulum stress by hyperglycemia is essential for Müller cell-derived inflammatory cytokine production in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Activation of protein kinase C isoforms and its impact on diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

The anthocyanin cyanidin-3-O-β-glucoside, a flavonoid, increases hepatic glutathione synthesis and protects hepatocytes against reactive oxygen species during hyperglycemia: Involvement of a cAMP-PKA-dependent signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Inflammation and cancer: back to Virchow?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Abnormal glucose metabolism and pancreatic cancer mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Roles of androgens in the development, growth, and carcinogenesis of the mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Serum oestradiol and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome, and normal controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Insulin-like growth factors in endometrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Nutrition, hormones, and breast cancer: is insulin the missing link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Diabetes mellitus and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

The effects of insulin-like growth factors on tumorigenesis and neoplastic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

21 January 2018

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Role of adipokines in complications related to obesity: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Circulating adiponectin and endometrial cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Genome-wide association study identifies a common variant associated with risk of endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Role of genetic polymorphisms and ovarian cancer susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Diabetes mellitus and ovarian cancer (Sweden).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Risk of cancer following hospitalization for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

CK2 as a positive regulator of Wnt signalling and tumourigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Breast cancer risk in young women and history of selected medical conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Selected medical conditions and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Fasting serum glucose level and cancer risk in Korean men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Prospective study of hyperglycemia and cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Diabetes mellitus and risk of breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

AGE-RAGE system and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

The effect of metformin on breast cancer outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Effect of Adiposity and Fat Distribution on Endometrial Cancer Risk in Shanghai Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

Ovarian cancer risk and history of selected medical conditions linked with female hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-015-3858-Z

10.1007/S00404-015-3858-Z

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference